Search

Your search keyword '"Kwok, Seung-Ki"' showing total 11 results
Start Over Author "Kwok, Seung-Ki" Journal international journal of rheumatic diseases
11 results on '"Kwok, Seung-Ki"'

1. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo‐controlled trial in North East Asia

Author

Suh, Chang‐Hee, primary, Lee, Yoonhee, additional, Yoo, Sang‐Bae, additional, Quasny, Holly, additional, Navarro Rojas, Aldo Amador, additional, Hammer, Anne, additional, Song, Yeong‐Wook, additional, Kang, Young Mo, additional, Cho, Chul‐Soo, additional, Park, Won, additional, Kwok, Seung‐Ki, additional, Lee, Seung‐Geun, additional, Chung, Won Tae, additional, and Bae, Sang‐Cheol, additional

Published
2023
Full Text
View/download PDF

2. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo‐controlled trial in North East Asia.

Author

Suh, Chang‐Hee, Lee, Yoonhee, Yoo, Sang‐Bae, Quasny, Holly, Navarro Rojas, Aldo Amador, Hammer, Anne, Song, Yeong‐Wook, Kang, Young Mo, Cho, Chul‐Soo, Park, Won, Kwok, Seung‐Ki, Lee, Seung‐Geun, Chung, Won Tae, and Bae, Sang‐Cheol

Subjects
SYSTEMIC lupus erythematosus, KOREANS, BELIMUMAB, CLINICAL trials, LUPUS erythematosus, AUTOANTIBODY analysis
Abstract

Aim: This post hoc analysis evaluated the efficacy and safety of intravenous belimumab 10 mg/kg in the South Korean subgroup of patients with systemic lupus erythematosus (SLE) enrolled in the North East Asia (NEA) study (GSK Study BEL113750; NCT01345253). Methods: NEA was a double‐blind, placebo‐controlled, randomized Phase 3 trial. Patients with active, autoantibody‐positive SLE were randomized 2:1 to belimumab or placebo plus standard therapy administered on Days 0, 14, and 28, and then every 28 days up to Week 48. The primary efficacy endpoint in this analysis was SLE Responder Index 4 (SRI‐4) response rate at Week 52, defined as the proportion of patients achieving a ≥4‐point reduction in Safety of Estrogens in Lupus Erythematosus National Assessment‐SLE Disease Activity Index (SELENA‐SLEDAI) score, no worsening (<0.3 increase from baseline) in Physician Global Assessment, no new British Isles Lupus Assessment Group (BILAG) A domain and <2 new BILAG B domain scores. Results: Among 100 South Korean patients enrolled in NEA, 54/66 (81.8%) belimumab‐ and 24/34 (70.6%) placebo‐treated patients completed the double‐blind phase. Significantly more belimumab‐ than placebo‐treated patients achieved SRI‐4 response at Week 52 (n = 35/66, 53.0% vs. n = 8/34, 23.5%; odds ratio [OR; 95% confidence interval (CI)]: 3.67 [1.45, 9.28]; p =.0061). The proportion of patients experiencing ≥1 adverse event was similar between groups (belimumab: n = 60/66, 90.9% vs. placebo: n = 31/34, 91.2%). No new safety signals emerged in this subgroup analysis. Conclusion: Belimumab was efficacious for the treatment of SLE and well tolerated among the South Korean subgroup of patients from the NEA study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Survival and prognostic factors in patients with connective tissue disease‐associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry

Author

Kang, Kwi Young, Jeon, Chan Hong, Choi, Sung Jae, Yoon, Bo Young, Choi, Chan‐Bum, Lee, Chang Hoon, Suh, Chang‐Hee, Lee, Choong Won, Cho, Chul Soo, Nam, Eon Jeong, Koh, Eun‐Mi, Kim, Ho‐Youn, Choi, Hyo Jin, Kim, Hyoun‐Ah, Jun, Jae‐Bum, Lee, Jaejoon, Kim, Jinseok, Ji, Jong Dae, Min, Jun Ki, Kim, Ki Jo, Shin, Kichul, So, Min Wook, Kwon, Seong Ryul, Kim, Seong‐Kyu, Nah, Seong‐Su, Kwok, Seung‐Ki, Lee, Soo‐Kon, Lee, Sung Won, Park, Sung‐Hwan, Park, Won, Park, Yong‐Beom, Lee, Young Ho, Lee, Shin‐Seok, and Yoo, Dae Hyun

Published
2017
Full Text
View/download PDF

9. Differences in quality of life determinants according to the presence of fibromyalgia in middle-aged female patients with systemic lupus erythematosus: a multicenter, cross-sectional, single-ethnicity cohort

Author

Moon, Su-Jin, primary, Kang, Kwi Young, additional, Kwok, Seung-Ki, additional, Ju, Ji Hyeon, additional, Hong, Yeon-Sik, additional, Park, Sung-Hwan, additional, Jeon, Chan Hong, additional, Choi, Sang Tae, additional, Song, Jung-Soo, additional, and Min, Jun-Ki, additional

Published
2018
Full Text
View/download PDF

10. Survival and prognostic factors in patients with connective tissue disease‐associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry

Author

Kang, Kwi Young, primary, Jeon, Chan Hong, additional, Choi, Sung Jae, additional, Yoon, Bo Young, additional, Choi, Chan‐Bum, additional, Lee, Chang Hoon, additional, Suh, Chang‐Hee, additional, Lee, Choong Won, additional, Cho, Chul Soo, additional, Nam, Eon Jeong, additional, Koh, Eun‐Mi, additional, Kim, Ho‐Youn, additional, Choi, Hyo Jin, additional, Kim, Hyoun‐Ah, additional, Jun, Jae‐Bum, additional, Lee, Jaejoon, additional, Kim, Jinseok, additional, Ji, Jong Dae, additional, Min, Jun Ki, additional, Kim, Ki Jo, additional, Shin, Kichul, additional, So, Min Wook, additional, Kwon, Seong Ryul, additional, Kim, Seong‐Kyu, additional, Nah, Seong‐Su, additional, Kwok, Seung‐Ki, additional, Lee, Soo‐Kon, additional, Lee, Sung Won, additional, Park, Sung‐Hwan, additional, Park, Won, additional, Park, Yong‐Beom, additional, Lee, Young Ho, additional, Lee, Shin‐Seok, additional, and Yoo, Dae Hyun, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results